Medical Therapy. Adverse Effects or Lack of Adverse Effects

Inhaled Nitric Oxide and Hypoxic Brain Injury in Newborn Piglets

Shadi Malaeb, John Grothusen, Ferit Tuzer, Maria Delivoria-PapadopoulosDrexel University College of Medicine. United States Nitric OxideNitric Oxide 2026; DOI: 10.1016/j.niox.2026.07.003 AbstractBackground: Inhaled nitric oxide (iNO) is widely used as a pulmonary vasodilator to treat infants with pulmonary hypertension (PHN). Hypoxia (Hx) and acidosis increase pulmonary vascular resistance and contribute to PHN. Perinatal asphyxia and resultant hypoxic-ischemic encephalopathy

Inhaled Nitric Oxide and Hypoxic Brain Injury in Newborn Piglets Read More »

Right Ventricular Function Improves With Pulmonary Vasodilator Treatment in Pediatric Patients With Pulmonary Hypertension and Multivessel Pulmonary Vein Stenosis in a Single Center Cohort

Catherine M. Avitabile, Kimberly Butler, Antara Mondal, David B. Frank, Yan Wang, Devon Ash, Laura Mercer‐Rosa, Michael L. O’Byrne, Ryan CallahanUniversity of Pennsylvania, Perelman School of Medicine and Children’s Hospital of Philadelphia. United States Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70346 AbstractPulmonary hypertension (PH) and right ventricular (RV) dysfunction increase mortality in multivessel pediatric pulmonary vein

Right Ventricular Function Improves With Pulmonary Vasodilator Treatment in Pediatric Patients With Pulmonary Hypertension and Multivessel Pulmonary Vein Stenosis in a Single Center Cohort Read More »

Prostaglandin Administration and Outcomes in Children on Extracorporeal Membrane Oxygenation

Weidi Xiao, Nedaa Aldairi, Brian S. Marcus, Matthew Weiss, Allison S. Cowl, Marissa Moncata, Akash Deep, Oliver KaramYale University, Yale New Haven Children’s Hospital and Yale School of Medicine. Dr. Sulaiman AlHabib Medical Group. Albert Einstein College of Medicine. Centre Mère-Enfant Soleil du CHU de Québec. Connecticut Children’s Medical Center. King’s College Hospital. United States,

Prostaglandin Administration and Outcomes in Children on Extracorporeal Membrane Oxygenation Read More »

Off-Label Sotatercept Use in Pediatric Pulmonary Arterial Hypertension: A Single-Center Retrospective Hemodynamic Study

Dhruv Rao, Shylah Haldeman, Jeanne Carroll, Rohit RaoUniversity of Arizona, Tucson. Rady Children’s Hospital-San Diego and University of California San DiegoUnited States Pediatric CardiologyPediatr Cardiol 2026; DOI: 10.1007/s00246-026-04349-2 AbstractSotatercept, a first-in-class activin signaling inhibitor, has demonstrated disease-modifying efficacy in adults with pulmonary arterial hypertension (PAH). Pediatric data remain limited to ongoing clinical trials. We conducted an

Off-Label Sotatercept Use in Pediatric Pulmonary Arterial Hypertension: A Single-Center Retrospective Hemodynamic Study Read More »

Inhalable extracellular vesicle delivered IL-10 mRNA attenuates pulmonary hypertension in rats

Guoliang Wang, Jie Liu, Peiyi Bai, Hong Jiao, Xiaohui Kong, Zhangke Guo, Gaopeng Li, Aijun LiuBeijing Children’s Hospital, Beijing Pediatric Research Institute, Capital Medical University and National Center for Children’s Health. Shanxi Bethune Hospital, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences and Tongji Shanxi Hospital. General Hospital of Taiyuan Iron and

Inhalable extracellular vesicle delivered IL-10 mRNA attenuates pulmonary hypertension in rats Read More »

Efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn: a systematic review and meta-analysis

Guanghong Li, Xiaoqun Du, Weibin Luo, Junhua Wei, Huiyi HuangHuadu District People’s Hospital of Guangzhou.China Frontiers in PediatricsFront Pediatr 2026; 14: DOI: 10.3389/fped.2026.1836276 AbstractObjective: To evaluate the efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn (PPHN).Methods: PubMed, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched from inception to March

Efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn: a systematic review and meta-analysis Read More »

Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc)

Kathryn S. Torok, Paulina Horvei, Jonathan Li, Franziska Rosser, Jessie L. Alexander, Kirsten Rose-felker, Vibha Sood, Adam Olson, Nicole Hogue, Vickie Vandergrift, Heather Stanczak, Maura Miglioretti, Lauren Farver, Wendy Koster, Devin Mcguire, Haley Havrilla, Shawna McIntyre, Robyn T. Domsic, Robert A. Lafyatis, Paul SzabolcsUniversity of Pittsburgh Medical Center (UPMC) and Children’s Hospital of Pittsburgh. Stanford

Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc) Read More »

Descriptive study of the effects of treprostinil and/or epoprostenol in newborn infants with inhaled NO refractory persistent pulmonary hypertension of the newborn (PPHN)

Charlotte Mazepa, Sébastien Mur, Géraldine Gascoind, Laurent Storme, Nicolas Joram, Caroline Viard, Yves Dulac, Marine Butini, Sophie BreinigChildren’s Hospital, CHU de Toulouse and Université de Toulouse. Lille University Hospital. Jeanne-de-Flandre Hospital and CHU de Lille. Nantes University Hospital. Hôpital Femme-Mère-Enfant, Hospices civils de Lyon and Université Claude-Bernard-Lyon. France TherapeuticsTherapie 2026; DOI: 10.1016/j.therap.2026.03.001 AbstractBackground: Epoprostenol and treprostinil, prostacyclin

Descriptive study of the effects of treprostinil and/or epoprostenol in newborn infants with inhaled NO refractory persistent pulmonary hypertension of the newborn (PPHN) Read More »

Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial

Wesley M. Jackson, Henry P. Foote, Nicole Stephenson, Steven M. Kemp, Ryan T. Moore, Christopher R. Nitkin, Dan Stewart, Gloria S. Pryhuber, John T. Berger, Ankita Shukla, Amand England, Stephanie M. Ford, Lance A. Parton, Jennifer F. Check, Mina H. Hanna, Megan Lagoski, Ramesh Krishnan, Kristen T. Leeman, Shilpa Vyas-Read, Mark L. Hudak, Anup C.

Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial Read More »

Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children

Meng Li, Yingchun Wang, Xiaoyu Hu, Haizhao Zhao, Weida Lu, Yuan Ji, Xiaopei CuiQilu Hospital and Cheeloo College of Medicine of Shandong University. China BioMedical Central PediatricsBMC Pediatr 2026; DOI: 10.1186/s12887-026-06954-9 AbstractBackground: Selexipag is an orally effective prostacyclin receptor agonist that has been approved for treating pulmonary arterial hypertension (PAH) in adults but is still used off-label

Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children Read More »

Scroll to Top